Toll-like Receptor (TLR)

Toll-like Receptor (TLR) designates a family of pattern recognition receptors that detect pathogen-associated molecular patterns and initiate innate immune responses, activating signalling pathways leading to cytokine production, inflammation, and adaptive immune activation. These receptors recognise microbial components such as lipopolysaccharides, nucleic acids, and viral proteins, playing central roles in host defence while contributing to inflammatory and autoimmune diseases when dysregulated.

The pharmaceutical industry targets TLR pathways for both immune activation and immune suppression applications. Vaccine adjuvants often leverage TLR agonists enhancing immune responses and improving vaccine efficacy. TLR agonists are investigated in oncology for stimulating anti-tumour immunity, while TLR antagonists aim to reduce excessive inflammation in autoimmune or inflammatory conditions. Drug development requires balancing desired immune modulation with risks of systemic inflammation, cytokine release, or immune-related adverse effects. Biomarker strategies monitor cytokine profiles and immune activation states. Preclinical studies evaluate receptor specificity, downstream signalling, and safety margins. As immunology understanding expands and therapeutic modalities diversify, TLR biology continues offering opportunities for immune modulation supporting vaccines, cancer therapies, and inflammatory disease interventions.